Artivion Closes $175M Deal for Aortic Arch Maker Endospan

Endospan announced that Artivion has closed the transaction to acquire the company.

This milestone follows April’s U.S. Food and Drug Administration (FDA) PMA approval of the Nexus aortic arch system, the first off-the-shelf endovascular solution designed to treat aortic arch disease, including chronic aortic dissections, in patients at high risk for open surgical repair.

The acquisition’s purchase for the acquisition is $175 million, less offsets for previously provided loans, plus a potential for up to $200 million in additional consideration contingent on U.S. Nexus commercial performance over the next two years.

This marks the integration of the Nexus system into a comprehensive global portfolio of solutions to treat the aortic arch. Endospan’s endovascular tech will be supported by a leading company in cardiac and vascular surgery, facilitating broader access.

“The FDA approval of the NEXUS system was a pivotal moment for aortic surgeons seeking a technology specifically designed to treat the ascending and aortic arch,” said Kevin Mayberry, CEO at Endospan. “With Artivion’s acquisition of Endospan, this differentiated technology is being positioned within a company that understands the aortic space through a differentiated portfolio serving the multidisciplinary approach of open, endo and hybrid solutions.”

Artivion has been the exclusive distributor of the Nexus system in the EMEA region since 2019. Endospan’s expanded portfolio in Europe, Asia-Pacific, and Latin America offers solutions ranging from off-the-shelf endovascular systems to custom-made multibranch configurations of Nexus Duo and Nexus Tre.

“Our acquisition of Endospan and its NEXUS system completes our market-leading, three-pronged aortic arch portfolio. This technology, alongside AMDS and ARCEVO LSA, positions us at the forefront of this segment as the only company globally with a complete portfolio of aortic arch solutions,” said Pat Mackin, Artivion chairman, president, and CEO of Artivion. “Further, NEXUS is a platform technology, not just a single product. With this acquisition, we are also adding a robust pipeline of next-generation arch technologies currently in development that we expect will further expand and strengthen our leadership position in the aortic arch market over time.”